Literature DB >> 18621927

Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels.

Serge Guerreiro1, Damien Toulorge, Etienne Hirsch, Marc Marien, Pierre Sokoloff, Patrick P Michel.   

Abstract

Epidemiological evidence suggests that caffeine or its metabolites reduce the risk of developing Parkinson's disease, possibly by protecting dopaminergic neurons, but the underlying mechanism is not clearly understood. Here, we show that the primary metabolite of caffeine, paraxanthine (PX; 1, 7-dimethylxanthine), was strongly protective against neurodegeneration and loss of synaptic function in a culture system of selective dopaminergic cell death. In contrast, caffeine itself afforded only marginal protection. The survival effect of PX was highly specific to dopaminergic neurons and independent of glial cell line-derived neurotrophic factor (GDNF). Nevertheless, PX had the potential to rescue dopaminergic neurons that had matured initially with and were then deprived of GDNF. The protective effect of PX was not mediated by blockade of adenosine receptors or by elevation of intracellular cAMP levels, two pharmacological effects typical of methylxanthine derivatives. Instead, it was attributable to a moderate increase in free cytosolic calcium via the activation of reticulum endoplasmic ryanodine receptor (RyR) channels. Consistent with these observations, PX and also ryanodine, the preferential agonist of RyRs, were protective in an unrelated paradigm of mitochondrial toxin-induced dopaminergic cell death. In conclusion, our data suggest that PX has a neuroprotective potential for diseased dopaminergic neurons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621927     DOI: 10.1124/mol.108.048207

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  24 in total

1.  Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.

Authors:  Patricia K Sonsalla; Lai-Yoong Wong; Suzan L Harris; Jason R Richardson; Ida Khobahy; Wenhao Li; Bharathi S Gadad; Dwight C German
Journal:  Exp Neurol       Date:  2012-01-28       Impact factor: 5.330

2.  Differential Effect of Caffeine Consumption on Diverse Brain Areas of Pregnant Rats.

Authors:  Inmaculada Ballesteros-Yáñez; Carlos Alberto Castillo; Mariano Amo-Salas; José Luis Albasanz; Mairena Martín
Journal:  J Caffeine Res       Date:  2012-06

Review 3.  Neuronal Ryanodine Receptors in Development and Aging.

Authors:  Nawaf Abu-Omar; Jogita Das; Vivian Szeto; Zhong-Ping Feng
Journal:  Mol Neurobiol       Date:  2017-01-19       Impact factor: 5.590

Review 4.  Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders.

Authors:  Vittorio Calabrese; Carolin Cornelius; Albena T Dinkova-Kostova; Edward J Calabrese; Mark P Mattson
Journal:  Antioxid Redox Signal       Date:  2010-08-28       Impact factor: 8.401

5.  Autophagy inhibition by caffeine increases toxicity of methamphetamine in SH-SY5Y neuroblastoma cell line.

Authors:  Rujiraporn Pitaksalee; Yupin Sanvarinda; Theerin Sinchai; Pantip Sanvarinda; Anusorn Thampithak; Nattinee Jantaratnotai; Surawat Jariyawat; Patoomratana Tuchinda; Piyarat Govitrapong; Pimtip Sanvarinda
Journal:  Neurotox Res       Date:  2015-01-15       Impact factor: 3.911

Review 6.  Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease.

Authors:  Simonetta Camandola; Natalie Plick; Mark P Mattson
Journal:  Neurochem Res       Date:  2018-02-08       Impact factor: 3.996

7.  Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice.

Authors:  Masashi Okuro; Nobuhiro Fujiki; Nozomu Kotorii; Yuji Ishimaru; Pierre Sokoloff; Seiji Nishino
Journal:  Sleep       Date:  2010-07       Impact factor: 5.849

8.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

9.  Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture.

Authors:  Fanny Schmidt; Pierre Champy; Blandine Séon-Méniel; Xavier Franck; Rita Raisman-Vozari; Bruno Figadère
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

10.  Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease.

Authors:  K Xu; Y-H Xu; J-F Chen; M A Schwarzschild
Journal:  Neuroscience       Date:  2010-02-16       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.